# C_2008288EN.01001101.xml

| 11.11.2008 | EN | Official Journal of the European Union | C 288/11 |
| --- | --- | --- | --- |

11.11.2008

EN

Official Journal of the European Union

C 288/11

---

Prior notification of a concentration

(Case COMP/M.5295 — Teva/Barr)

(Text with EEA relevance)

(2008/C 288/06)

| 1. | On 3 November 2008, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Teva Pharmaceutical Industries Limited (‘Teva’, Israel), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Barr Pharmaceuticals Inc. (‘Barr’, U.S.A). |
| --- | --- |

1.

On 3 November 2008, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Teva Pharmaceutical Industries Limited (‘Teva’, Israel), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Barr Pharmaceuticals Inc. (‘Barr’, U.S.A).

1

| 2. | The business activities of the undertakings concerned are:






  — | for Teva: development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Teva: development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients,

| — | for Barr: development, production and marketing of generic and proprietary branded pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. |
| --- | --- |

—

for Barr: development, production and marketing of generic and proprietary branded pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5295 — Teva/Barr, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5295 — Teva/Barr, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---